[Valdecoxib (Bextra)].
Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain.
Scheen
A J
AJ
Université de Liège.
Malaise
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004412:Dysmenorrhea / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D007555:Isoxazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy; D010149:Postoperative Pain / Q000188:drug therapy; D011355:Prodrugs; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D007555:Isoxazoles; D011355:Prodrugs; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides